Zhenglong Li1, Xingming Jiang1, Zhilei Su1, Jinglin Li1, Pengcheng Kang1, Chunlong Li1, Yunfu Cui2. 1. Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China. 2. Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China. Electronic address: yfcui777@hotmail.com.
Abstract
OBJECTIVES: A vast of transcripts have been found aberrantly expressed in cancers functioning as mechanical factors. The association between the deregulation of long noncoding RNAs (lncRNAs) and clinicopathologic features is one of the most investigated in this field, and many lncRNAs have already been revealed to be potential biomarkers or therapeutic targets. Zinc finger antisense 1 (ZFAS1) has been found one promising lncRNA, initially discovered downregulated in human breast cancer and could regulate alveolar development and epithelial cell differentiation in mice mammary gland, however the subsequent investigation provided inverse outcomes as overexpressed in other human cancers. Further excavation of this transcript indicated that ZFAS1 could function as oncogenic factor via many approaches to contribute to the advance of cancers, including induction of epithelial-mesenchymal transition, sponging microRNAs, destabilization p53 gene and many others. MATERIALS AND METHODS: In this work, we summarized current evidence regarding the biological functions and mechanisms of ZFAS1 in human cancers. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library. RESULTS: LncRNA ZFAS1 is one cancer-implicated product with multiple functional mechanisms, and its potential clinical values is gradually unfolded in many types of cancers, including breast cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioma, ovarian cancer and many others. CONCLUSION: The multi-mechanisms of lncRNA ZFAS1 fertilizes its role of potential clinical biomarkers and therapeutic targets.
OBJECTIVES: A vast of transcripts have been found aberrantly expressed in cancers functioning as mechanical factors. The association between the deregulation of long noncoding RNAs (lncRNAs) and clinicopathologic features is one of the most investigated in this field, and many lncRNAs have already been revealed to be potential biomarkers or therapeutic targets. Zinc finger antisense 1 (ZFAS1) has been found one promising lncRNA, initially discovered downregulated in humanbreast cancer and could regulate alveolar development and epithelial cell differentiation in mice mammary gland, however the subsequent investigation provided inverse outcomes as overexpressed in other humancancers. Further excavation of this transcript indicated that ZFAS1 could function as oncogenic factor via many approaches to contribute to the advance of cancers, including induction of epithelial-mesenchymal transition, sponging microRNAs, destabilization p53 gene and many others. MATERIALS AND METHODS: In this work, we summarized current evidence regarding the biological functions and mechanisms of ZFAS1 in humancancers. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library. RESULTS: LncRNA ZFAS1 is one cancer-implicated product with multiple functional mechanisms, and its potential clinical values is gradually unfolded in many types of cancers, including breast cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioma, ovarian cancer and many others. CONCLUSION: The multi-mechanisms of lncRNA ZFAS1 fertilizes its role of potential clinical biomarkers and therapeutic targets.